Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, Advisory Panel Agree: Post-Hoc Analyses Won't Fly

This article was originally published in The Gray Sheet

Executive Summary

CDRH's critique of Guidant's post-hoc analysis of its Contak CD data sends a clear warning to sponsors who attempt to draw positive conclusions about one subgroup from an inconclusive clinical trial.

You may also be interested in...



NMT STARFlex Single-Arm Study Insufficient For Approval, Panel Concludes

NMT Medical must conduct a randomized controlled trial of the STARFlex septal occlusion system to demonstrate that the device is superior to medical therapy in preventing strokes, FDA's Circulatory System Devices Panel concluded at its Sept. 10 meeting in Gaithersburg, Maryland

NMT STARFlex Single-Arm Study Insufficient For Approval, Panel Concludes

NMT Medical must conduct a randomized controlled trial of the STARFlex septal occlusion system to demonstrate that the device is superior to medical therapy in preventing strokes, FDA's Circulatory System Devices Panel concluded at its Sept. 10 meeting in Gaithersburg, Maryland

Medtronic InSync ICD Gains Panel Support In Tiebreaking 6-5 Vote

The recommended post-market requirement for Medtronic's InSync ICD and its pacing counterpart suggests that companies that conduct pivotal studies with a small number of patients will be expected to follow up with a large trial

Related Content

UsernamePublicRestriction

Register

MT015145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel